Human papillomavirus testing using HPV APTIMA® assay and an external cellularity control in self‐collected samples

Abstract

AbstractIn cervical cancer screening programs, the detection of high‐risk human papillomavirus (HR‐HPV) is now widely implemented on physician‐collected samples and has expanded to include self‐collected samples. The use of a cellularity control (CC) is needed to reduce false‐negative HPV results. An external mRNA CC for the HPV APTIMA® assay was assessed for its analytical performance and the results were compared with both cervix cytobrush samples taken by physicians and self‐collected vaginal samples from 148 women. The performance of the CC was adjusted to control for the presence of cellular mRNA in the ThinPrep® and Multitest® transport media. This CC is user‐friendly but implies to perform two independent assays on PANTHER® automate. Self‐collected vaginal sampling gives a lower median CC results (13.2 vs. 16.9 min) but a higher risk of negative CC results (3.3 vs. 0%). The usefulness of the CC for the HR‐HPV assay may be optimized by the definition of a threshold for a minimum cell number to be tested to increase confidence in HPV‐negative results. The systematic use of an RNA CC increases confidence for HPV RNA assays on self‐collected vaginal samples.